NextCure, Inc. (NXTC)
NASDAQ: NXTC · Real-Time Price · USD
5.80
+1.40 (31.82%)
Aug 4, 2026, 2:58 PM EDT - Market open
NextCure Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
40
Market Cap
20.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | - | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Moolec Science | 7.83M |
| OSR Health | 2.63M |
| Cyclerion Therapeutics | 1.99M |
| BioLineRx | 1.40M |
| Vyome Holdings | 152.72K |
NXTC News
- 19 days ago - NextCure trading resumes - TheFly
- 19 days ago - NextCure trading halted, volatility trading pause - TheFly
- 21 days ago - Why Is Penny Stock NextCure (NXTC) Up Today? - TipRanks
- 21 days ago - NextCure, Avere Therapeutics enter definitive merger agreement - TheFly
- 21 days ago - NextCure, Avere Therapeutics enter definitive merger agreement - TheFly
- 21 days ago - NextCure and Avere Therapeutics Announce Merger to Advance Once-Weekly Oral IL-23 Therapy - GlobeNewsWire
- 4 weeks ago - NextCure Slides: Corporate presentation - Filings
- 6 weeks ago - NextCure Transcript: AGM 2026 - Transcripts